Atrium; Fibrillation
12
3
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Abbott Atrial Fibrillation Post Approval Study
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation
Personalised Ablation Strategies in AF
Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
Retrieval of Economic Incentives and Information on Quality-of-care Indicators in Primary Care
The Atherogenic Index of Plasma（AIP） in Patients With Atrial Fibrillation
The Short and Long-term Cardiovascular Consequences of Critical Illness: The C3 Study
Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation
Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation
Echocardiographic Left Atrial Function Assessment and Atrial Fibrillation Post-Coronary Artery Bypass Surgery
Enhanced Diagnostics for Early Detection of Atrial Fibrillation - Prospective Validation